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The modern pharmaceutics actively screens an
immense diversity of substances occurring in plants
and other natural resources in the search for new effective medicinal agents. The Global Institute for Bioexploration (GIBEX) established by joint efforts of Rutgers University and the University of Illinois (United
States) represents the organizational core of international scientific community whose activity is directed
towards the search and development of new medicinal
preparations from natural raw materials. The basis of
GIBEX activity is the transfer of modern screening
technologies to countries and geographical regions
characterized by remarkable biodiversity. The GIBEX
goals are to encourage the search for new natural biologically active substances, to maintain biodiversity,
and to monitor the natural resources conservation.
USE OF NATURAL RESOURCES
FOR DEVELOPMENT OF MEDICINAL AGENTS
AND BIOLOGICALLY ACTIVE ADDITIVES
From immemorial time the plants have been used
not only for food but also as a source of biologically
active substances. The use of plants for medicinal purposes was documented in Sumerian manuscripts more
than 5000 years ago. The substances of plant origin
were for long the only source of medicinal drugs [1].
However, even presently these substances are extensively used in the health care practice. The discovery
and exploration of alkaloids opened way to obtaining
chemically uniform monomolecular medicines of natural origin [2]. Even in the era of combinatory chemistry,
more than 25% of new medicinal agents are related in
some way to substances of plant origin [3]. The rapidly
growing application of preparations from sweet wormwood (Artemisia annua L.) in the struggle against
malaria [4] is a demonstrative example of effectiveness
of herbal medicines.
Among 847 low-molecular-weight medicines introduced into the practice since 1981, 43 agents belong to
natural compounds, and 232 agents are derivatives of
natural substances. Furthermore, in the rest group of
572 preparations, the original link to natural compounds is traced for 262 preparations [5]. According to
our estimates, more than 200000 of various low-molec-

ular-weight substances were obtained from plant materials.
The plants evolved as chemical factories capturing
energy from the Sun for the production of a large variety of compounds that are needed not only for the construction and functioning of the plant organism but also
for plant protection against adverse environmental factors and for strengthening the competitiveness of a
given species in the plant community [6]. The chemical
defense is almost the only effective instrument in the
struggle of plants against pathogenic organisms and
multiple herbivorous animals. For the effective defense
against pathogens, plants have developed a complicated
system comprising the elements with different mechanisms of action. Recently, scientists from Boston
(United States) have shown that Berberis fremontii Torrey possesses at least two complementary mechanisms
defending the plant against microorganism attacks [7].
The antibacterial activity of alkaloids is supplemented
and reinforced by the operation of specific inhibitors of
the bacterial transporter responsible for the resistance
to antibiotics.
Owing to these complementary effects, multi-componential plant extracts might be highly effective as
therapeutic agents. Interactions of chemical components in the extracts play an important role in effectiveness of plant preparations. For example, an alkaloid
triptolide from Tripterygium wilfordii Hook F., effective for therapy of rheumatoid arthritis, is highly toxic
for humans in purified form, although the toxicity of
nonpurified triptolide in plant extracts is significantly
reduced. Because of its high toxicity, the purified triptolide has never been allowed for therapeutic usage,
whereas the medicine based on T. wilfordii extracts is
currently at the final stage of development [8]. The
effectiveness of nonpurified plant preparations, as compared to that of purified ingredients, might involve
other mechanisms such as protection of active substance from the attack of “foreign” enzymes, a faster
transfer of the active substance across membranes, and
circumvention of drug resistance of human organisms.
Presently, there is a growing interest in mechanisms
underlying the action of plant-derived substances on
gene activities involved in disease development or vital
functions of the organism [9].
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According to estimates of the World Health Organization (WHO), about 80% of the population in the
developing countries relies on plant preparations in
therapy of diseases [10]. Traditionally, plant preparations are widely used in pharmacopeias of Japan, Germany, and other European countries. In the United
States, medicinal plant preparations were allowed for
registration not long ago; however, the majority of such
preparations are widely used in the United States as
dietary supplements. In many countries of the world,
bioactive preparations of natural origin are also widely
applied as biologically active dietary supplements
(nutraceutics).
According to data of the Food and Agriculture Organization (FAO), more than 50000 plant species are used
in the traditional folk medicine throughout the world
[11]. The highest percentage of native flora species
used for medication is observed in countries of Southeast Asia, such as India (20%) and China (19%). In the
United States and Russia, slightly more than 10% of
plant species are used for therapeutic purposes.
The chemical diversity of the plant kingdom
remains largely unexplored. Even less is known about
biological activity of chemical substances obtained
from plants. The diverse and unique flora of our planet
is an enormous source of future prospects for biotherapy and improvement of public health care. However,
the boosted research and implementation of methods
for obtaining medicinal agents from natural raw materials is directly related to the problem of biodiversity
conservation [12]. Unfortunately, natural resources are
being rapidly exhausted because of sweeping urbanization, destruction of natural communities, and pollution
of the environment. Disappearance of any biological
species deprives the humankind forever of the access to
thousands of biologically active substances that might
potentially be a useful source of medicinal or other
chemical compounds. The conference of the United
Nations held in Rio de Janeiro in 1992 stated that biodiversity, including genetic and chemical diversity of natural resources, is an indispensible component of the
national heritage [13]. The adopted Declaration of the
conference proclaimed that “activities within the jurisdiction or control” of sovereign States “should not
cause damage to the environment of other States or of
areas beyond the limits of national jurisdiction.” In the
contemporary dynamic community, with its progressively increasing population and rapid industrial development, the conservation of natural resources is inseparable from rational usage of these resources.
GLOBAL INSTITUTE
FOR BIOEXPLORATION (GIBEX)
The intensive search for medicinal substances from
natural resources reached its peak in the period from the
1960s to the 1980s [3]. Presently, the interest reappears
to medicinal preparations obtained from natural raw
materials [14]. The international “Biotherapeutic initiaRUSSIAN JOURNAL OF PLANT PHYSIOLOGY
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tive for the research and development of natural biologically active substances” originated in the very beginning of the 21st century at Rutgers University (New Jersey, United States) and provided the basis for Global
Institute for Bioexploration (GIBEX). Later on GIBEX
was established by joint efforts of Rutgers University
and the University of Illinois at Urbana-Champaign
(United States).
GIBEX is an organizational core of the virtual international scientific community whose activity is aimed
at the research of new medications from natural
resources. GIBEX coordinates the work of more than
two dozens of national and regional divisions and affiliated organizations. The GIBEX activity is aimed at the
inventory of biological effects of natural compounds.
The objective of these efforts is similar to aspirations of
the academician N.I. Vavilov who managed to collect
unique genetic material in many remote places around
the world in the first half of the 20th century.
The goals of GIBEX include the encouraging of
new initiatives in research and development of natural
biologically active substances, the maintenance of
biodiversity, and conservation of natural resources. An
important integral part includes permanent efforts to
retain the cultural and natural heritage of member countries, including the historical experience of folk medicine. The basic principle of GIBEX activity is the transfer of modern technologies in research and development of medicinal agents to member countries within
the framework of comprehensive collaboration. The
GIBEX activities in world regions should promote the
detection, exploration, development, and marketing of
new therapeutic agents based on natural products of
herbal, fungal, and bacterial origin that are prospective
for distribution in the form of medicines, dietary supplements, and health-promoting food ingredients.
Until recently, there was a sustained trend to collect
natural materials in remote regions of developing countries and transport raw materials to the developed countries for pharmacological screening and creation of new
medicinal agents. This practice has raised numerous
political, social, and juristic problems. The intention of
GIBEX is to radically redirect the processes of bioresource detection and assessment. Within the framework
of new international “Biotherapeutic initiative,” the
portable field equipment and field-oriented methods for
pharmacological screening are being transferred
directly to bioresource-possessing countries. This is an
entirely new and highly ethical approach to the obtaining of natural biologically active substances from natural raw materials.
The majority of developing regions do not participate on an equal basis in pre-clinical and clinical
research and development of medicinal agents from
local flora and fauna. In turn, GIBEX considers its own
duty to provide scientific information and organizational basis for such investigations, relying mostly on
local personnel and resources. Thus, in full conformity
No. 4
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with general principles of equitable access to genetic
resources sharing benefits from exploitation of these
resources, the maximal value and profit is ensured to
countries bound by the license agreement concerning
new medications from local bioresources.
Scientific personnel from the developing regions are
usually trained in large research centers. This approach
is expensive and not always effective, because it often
leads to “brain drain” exerting detrimental influence on
regional economies. The international “Biotherapeutic
initiative” encourages scientists from the leading
world-known laboratories to work in the countries
involved in the bio-exploration program. This would
help regional specialists to master technologies for
selecting and detecting promising sources of medications and for conducting indispensable pharmacological studies. The educational component of these programs includes laboratory studies, practical field training, lectures, seminars, scientific conferences, and
public relation activities. The trainees can obtain
respective certificates from educational organizations
involved in the program.
Being adhered to the principle of research development in the areas of natural resources, GIBEX sends to
these regions highly qualified professionals with the
purpose of teaching local personnel and conducting
joint research in the copartner laboratories. Portable
instruments for biological screening, which are transferred to regional or national GIBEX branches, provide
for the field screening of biologically active substances
and accelerate the identification of promising therapeutic agents, while guaranteeing the intellectual property
rights for regional scientists.
Specific research goals of GIBEX and its national
branches set the new principle of conducting the
screening in the areas of potential sources of biologically active substances. The implementation of this
principle would preclude the export of biological materials for primary screening and would ensure full compliance with international agreements. Presently, 16
portable mobile and reliable tests are being used under
field conditions. These tests are aimed at the detection
of antibacterial, fungicidal, and antihelminthic activities. An important aim of the screening is to reveal characteristics closely related to the potential use of herbal
extracts for the prevention and cure of diseases. Such
characteristics include the inhibition of proteinase, glucosidase, and lipase, as well as evaluation of total content of phenol derivatives, anthocyanins, and antioxidants.
In addition, the GIBEX activity includes the invention of new technologies for preclinical and clinical
tests, improvement of their infrastructure, optimization
of medicinal plant growing, and standardization and
production of medications from natural raw materials.
A particular significance is devoted to devising and
accomplishing the strategy for protection and documentation of biodiversity and to completing the inven-

tory of natural bioresources and source organisms.
GIBEX is motivated to reinforce protection of intellectual property rights and to fulfill obligations according
to the Biodiversity Convention and regulations of the
World Trade Organization concerning the intellectual
property rights. While possessing the intellectual property rights, the member country can provide commercial licenses on the conditions acceptable for the country.
The exploration of new natural biologically active
substances at Rutgers University is mainly performed
at the School of Environmental and Biological Sciences. The faculty of this school are involved in numerous international programs dealing with biodiversity in
many countries of Asia, Africa, Europe, Australia,
North and South America, and also in the World Ocean.
The financial support of these programs, coming
largely from the United States Government, equals to
four million dollars per year. For example, the program
of International Cooperative Biodiversity Groups
(ICBG), established by the governmental structures of
the United States, is being implemented in Kazakhstan,
Kyrgyzstan, Tajikistan, and Uzbekistan with participation of six research groups from Rutgers University and
at least 60 scientists from Central Asia. A widely
known program of New Use Agriculture and the Natural Plant Product (NUANPP) is actively implemented
in four African countries. The teachers from Rutgers
University keep executive position in three out of five
Centers for Botanical Studies financed by National
Institutes of Health of the United States.
The activity of the Fairbrothers Plant Resources
Center is an important initiative directed at the maintenance and enlargement of the herbarium, mycological
museum, and the collection of plant extracts gathered at
Rutgers University. This activity also serves to the use
of these collections for conducting international botanical investigations and educational programs. GIBEX
extensively uses abundant collections of Entomological
Museum and the Center of Deepwater Ecology. The
scientists from the Cook College engaged in the search
of new biotherapeutics, cooperate with pharmaceutical,
food-producing, and chemical companies in the United
States and other countries. More than 50 specialists
from Rutgers University are associated with to GIBEX.
The leading partner of Rutgers University in GIBEX
is the University of Illinois at Urbana-Champaign
(United States). Both universities cooperate closely in
large collaborative projects concerning the search for
new biotherapeutic substances in Central Asia. Based
on profound international experience and extensive
facilities for investigation of natural products, the University of Illinois keeps close contacts with many countries such as Egypt, Jordan, Mexico, New Zealand,
Honduras, France, and China, which provides additional possibilities of using resources of these countries.
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The global goals of GIBEX necessitate a global
approach. The international cooperation within the
framework of GIBEX has already expanded to all continents and comprises such countries as Brazil, Ghana,
Israel, Kazakhstan, Kyrgyzstan, Nigeria, New Zealand,
Senegal, United States, Tanzania, Tajikistan, Uzbekistan, Ukraine, Chile, Switzerland, Ecuador, and Republic of South Africa.
The coordinated activities within the framework of
a new world consortium, GIBEX has already brought
first positive outcomes. In spring of 2007 a research
team from Rutgers University successfully transferred
their technological designs for field quantification of
bioactivity of plant extracts and trained a group of specialists from the University of Dar es Salaam (Tanzania). More than two thousand extracts were tested for
bioactivity under standard conditions. The first promising preparations were selected for the development of
anti-inflammatory agents and medications for the fight
against cancer and diabetes. Presently, active negotiations are conducted with several biotechnological and
pharmaceutical companies concerning the licensing of
test results obtained within the framework of GIBEX.
Eleven preparations have been already licensed by the
American biotechnological company for further development.
The international Biotherapeutic Initiative for
Exploration and Development of Natural Biologically
Active Substances launched by GIBEX expands rapidly, thus acquiring a number of new supporters and
participants in various regions of the World.
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